Trials / Completed
CompletedNCT00036166
Study of FK463 for the Treatment of Invasive Aspergillosis
An Open-Label, Non-Comparative Study of FK463 for the Treatment of Invasive Aspergillosis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 326 (actual)
- Sponsor
- Astellas Pharma Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate the safety and efficacy of FK463 in patients with proven or probable invasive infections due to Aspergillus species.
Detailed description
This will be an open-label, non-comparative study of intravenous FK463. Enrollment will include at least 100 patients evaluable for efficacy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | FK463 |
Timeline
- Start date
- 1999-01-29
- Primary completion
- 2002-01-31
- Completion
- 2002-01-31
- First posted
- 2002-05-09
- Last updated
- 2018-01-10
Locations
23 sites across 8 countries: Austria, France, Germany, Italy, Poland, Spain, Sweden, United Kingdom
Source: ClinicalTrials.gov record NCT00036166. Inclusion in this directory is not an endorsement.